During the last session, Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s traded shares were 0.77 million, with the beta value of the company hitting 2.97. At the end of the trading day, the stock’s price was $18.05, reflecting an intraday gain of 9.99% or $1.64. The 52-week high for the ARCT share is $45.00, that puts it down -149.31 from that peak though still a striking 20.78% gain since the share price plummeted to a 52-week low of $14.30. The company’s market capitalization is $488.92M, and the average intraday trading volume over the past 10 days was 0.38 million shares, and the average trade volume was 420.68K shares over the past three months.
Arcturus Therapeutics Holdings Inc (ARCT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ARCT has a Sell rating from 1 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) trade information
Arcturus Therapeutics Holdings Inc (ARCT) registered a 9.99% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 9.99% in intraday trading to $18.05, hitting a weekly high. The stock’s 5-day price performance is 11.49%, and it has moved by 7.70% in 30 days. Based on these gigs, the overall price performance for the year is -53.44%. The short interest in Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) is 4.54 million shares and it means that shorts have 11.34 day(s) to cover.
The consensus price target of analysts on Wall Street is $10.58, which implies a decrease of -70.6% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10.58 and $10.58 respectively. As a result, ARCT is trading at a premium of 41.39% off the target high and 41.39% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.40%. While earnings are projected to return -143.22% in 2025.
ARCT Dividends
Arcturus Therapeutics Holdings Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)’s Major holders
Arcturus Therapeutics Holdings Inc insiders own 8.46% of total outstanding shares while institutional holders control 87.34%, with the float percentage being 95.41%. FEDERATED HERMES, INC. is the largest shareholder of the company, while 233.0 institutions own stock in it. As of 2024-06-30, the company held over 4.69 million shares (or 17.4067% of all shares), a total value of $114.3 million in shares.
The next largest institutional holding, with 2.65 million shares, is of BLACKROCK INC.’s that is approximately 9.8262% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $64.52 million.
Also, the Mutual Funds coming in first place with the largest holdings of Arcturus Therapeutics Holdings Inc (ARCT) shares are Federated Hermes Kaufmann Fund and Federated Hermes Kaufmann Small Cap Fund . Data provided on Oct 31, 2024 indicates that Federated Hermes Kaufmann Fund owns about 2.44 shares. This amounts to just over 8.99 percent of the company’s overall shares, with a $43.97 million market value. The same data shows that the other fund manager holds slightly less at 2.2, or about 8.11% of the stock, which is worth about $39.67 million.
